Abstracts tagged "Bone density"

Abstract Number: 330 • 2017 ACR/ARHP Annual Meeting
Change in Bone Mineral Density in Patients with Rheumatoid Arthritis: Minimal 10-Year Follow-up
Hiraku Motomura, Isao Matsushita, Toshihito Hiraiwa and Tomoatsu Kimura, Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: To investigate the long-term change in bone mineral density (BMD) in patients with rheumatoid arthritis (RA). Methods: In a longitudinal study of 40 patients…
Abstract Number: 331 • 2017 ACR/ARHP Annual Meeting
Case Series: Comparison of Repository Corticotropin Injection (H.P. Acthar Gel) Versus Glucocorticoids on Bone Density in SLE Patients
Anny T. Wu¹ and Joshua June², ¹Rheumatology, Franciscan Alliance, Munster, IN, ²3394 E Jolly Rd Ste C, Great Lakes Center of Rheumatology, Lansing, MI
Background/Purpose: Repository Corticotropin Injection (RCI) is an adrenocorticotropin hormone in 16% gelatin with a prolonged release after intramuscular (IM) or subcutaneous injection. Adverse effects of…
Abstract Number: 334 • 2017 ACR/ARHP Annual Meeting
Comparison of Outcomes in Osteoporosis in Patients on Denosumab between Standard and Non-Standard Dosing Intervals
Nouman A. Syed, Mohammed Wiqar, Douglas Einstadter and Marina N. Magrey, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Denosumab (Dmab) is an antiresorptive agent with an approximate half-life of 26 days and according to the prescribing information the recommended dose is 60…
Abstract Number: 1218 • 2017 ACR/ARHP Annual Meeting
Caffeine Consumption and Risk of Osteoporosis: A Cross Sectional Study of 3, 210 Patients from the National Health and Nutrition Examination Survey
Nicola Berman¹, Teresa Attina², Bruce Cronstein¹, Stephen Honig¹ and Michael Pillinger¹, ¹Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ²Pediatrics, New York University School of Medicine, New York, NY
Background/Purpose: Adenosine regulates bone metabolism. In vitro studies suggest that direct stimulation of the adenosine A2A receptor increases osteoblasts and diminishes osteoclasts, and thus inhibition…
Abstract Number: 1222 • 2017 ACR/ARHP Annual Meeting
Impact of Bariatric Surgery on Bone Mineral Density : Observational Study of 110 Patients Followed up in a Specialised Centre for the Treatment of Obesity in France
Marion Geoffroy¹, Isabelle Lambrecht¹, Jan Chrusciel², Isabelle Gaubil-Kaladjian³, Ana Diaz-Cives⁴, Jean Paul Eschard¹ and Jean-Hugues Salmon¹, ¹Service de Rhumatologie, CHU Reims, Hôpital Maison Blanche, Reims, France, ²Service de Recherche Clinique, CHU Reims, Hôpital Robert Debré, Reims, France, ³Service d’Endocrinologie et nutrition, CHU Reims, Hôpital Robert Debré, Reims, France, ⁴Service de chirurgie digestive, CHU Reims, Hôpital Robert Debré, Reims, France
Background/Purpose: Bariatric surgery is used to treat severe obesity. We aimed to investigate the incidence of significant bone mineral density (BMD) loss at 6 and…
Abstract Number: 1223 • 2017 ACR/ARHP Annual Meeting
Inflammatory Bowel Diseases and the Risks of Fracture and Low Mineral Density: Review of the Literature and Meta-Analysis of Observational Cohorts
Paulina Szafors¹, Thomas Barnetche², Cédric Lukas³, Jacques Morel⁴, Cécile Gaujoux-Viala^5,6, Bernard Combe⁷ and Hélène Che⁸, ¹Department of Rheumatology, Lapeyronie Hospital and University of Montpellier, Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ⁵Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁶EA 2415, Montpellier University, Nîmes, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁸Rheumatology, University and Hospital Lapeyronie, University of Montpellier, France
Background/Purpose: Inflammatory bowel diseases (IBD), such as Crohn disease (CD) and ulcerative colitis (UC), are associated with a decreased bone mineral density caused by chronic…
Abstract Number: 2L • 2016 ACR/ARHP Annual Meeting
Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study
K Saag¹, RB Wagman², P Geusens³, JD Adachi⁴, O Messina⁵, R Emkey⁶, R Chapurlat⁷, NS Daizadeh², N Pannacciulli² and WF Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aires, Argentina, ⁶Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁷Hôpital Edouard Herriot, Lyon, France, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. Despite approved therapies, many subjects do not receive GIOP prevention or treatment.…
Abstract Number: 365 • 2016 ACR/ARHP Annual Meeting
Osteonecrosis of the Femoral Head Is Associated with Low Bone Mass.
muhammad soyfoo¹, Valérie Gangji², rodrigo moreno³, Joanne Rasschaert⁴ and Jean-Philippe Hauzeur⁵, ¹Rheumatology, Hôpital erasme, bruxelles, Belgium, ²Rheumatology, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium, ³nuclear medicine, erasme hospital, brussels, Belgium, ⁴Laboratory of Bone and Metabolic Biochemistry, Université Libre de Bruxelles, Brussels, Belgium, ⁵Rheumatology, Sart Tilman, Liège, Belgium
Background/Purpose: Osteonecrosis of the femoral head (ONFH) is characterized by epiphyseal necrosis that can lead to sub-chondral fracture, femoral head collapse and hip replacement. Osteoporosis…
Abstract Number: 513 • 2016 ACR/ARHP Annual Meeting
Low Serum 25-Hydroxyvitamin D Level Is Not Associated with Decreased Bone Mass or Bone Quality in Patients with Rheumatoid Arthritis
Kentaro Inui¹, Tatsuya Koike², Yuko Sugioka³, Tadashi Okano¹, Kenji Mamoto⁴, Masahiro Tada⁵ and Hiroaki Nakamura⁴, ¹Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Center for Senile Degenerative Disorders, Osaka City University Medical School, Osaka, Japan, ³Center for Senile Degenerative Disorders (CSDD), Osaka City University Medical School, Osaka, Japan, ⁴Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁵Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan
Background/Purpose: Vitamin D deficiency in patients with rheumatoid arthritis (RA) is commonly observed. Previous studies have investigated the relationship between vitamin D deficiency and RA…
Abstract Number: 1024 • 2016 ACR/ARHP Annual Meeting
Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial
B Langdahl¹, C Libanati², DB Crittenden³, MA Bolognese⁴, JP Brown⁵, NS Daizadeh³, K Engelke⁶, HK Genant⁷, S Goemaere⁸, Lars Hyldstrup⁹, E Jodar-Gimeno¹⁰, TM Keaveny¹¹, D Kendler¹², P Lakatos¹³, J Maddox³, J Malouf¹⁴, FE Massari¹⁵, JF Molina¹⁶, MR Ulla¹⁷ and A Grauer³, ¹Aarhus University Hospital, Aarhus, Denmark, ²UCB Pharma, Brussels, Belgium, ³Amgen Inc., Thousand Oaks, CA, ⁴Bethesda Health Research Center, Bethesda, MD, ⁵Laval University and CHU de Québec (CHUL) Research Centre, Quebec City, QC, Canada, ⁶BioClinica Inc., Hamburg, Germany, ⁷Department of Radiology, University of California San Francisco, San Francisco, CA, ⁸Ghent University Hospital, Gent, Belgium, ⁹Hvidovre University Hospital, Hvidovre, Denmark, ¹⁰Servicio de Endocrinología, Hospital Universitario Quirón, Madrid, Spain, ¹¹University of California at Berkeley, Berkeley, CA, ¹²University of British Columbia, Vancouver, BC, Canada, ¹³Department of Medicine, Semmelweis University, Budapest, Hungary, ¹⁴Universitat Autònoma de Barcelona, Barcelona, Spain, ¹⁵Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ¹⁶Reumalab Centro Integral de Reumatologia, Medellin, Colombia, ¹⁷Instituto Latinoamericano de Investigaciones Médicas, Córdoba, Argentina
Background/Purpose: STRUCTURE was a phase 3, open-label study evaluating the effect of romosozumab or teriparatide for 12 months in women with postmenopausal osteoporosis transitioning from…
Abstract Number: 1531 • 2016 ACR/ARHP Annual Meeting
Decrease in Bone Mineral Density during Three Months of Early RA Measured By DXR Predicts Radiographic Joint Damage after One Year
Michael Ziegelasch¹, Kristina Forslind², Thomas Skogh³, Katrine Riklund⁴, Alf Kastbom⁵ and E. Berglin⁶, ¹Rheumatology/AIR, Linköping, Sweden, ²Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ³IKE/Rheumatology, Linköping University, Linköping, Sweden, ⁴Departments of Diagnostic radiology, Umeå university, Umeå, Sweden, ⁵Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, ⁶Department of Publiic Health and Clinical Medicin/Rheumatology, Umeå university, Umea, Sweden
Background/Purpose: Digital X-ray radiogrammetry (DXR) is a method to calculate peripheral bone mineral density (BMD) which calculates BMD of the hands (DXR-BMD). The aim…
Abstract Number: 2541 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Use and Low Thoracic Bone Mineral Density Are Predictors for Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study
Kenji Mamoto¹, Kentaro Inui², Tadashi Okano¹, Yuko Sugioka³, Masahiro Tada⁴, Tatsuya Koike⁵ and Hiroaki Nakamura⁶, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatology & Orthopaedics, Higashisumiyoshi Morimoto Hospital, Osaka, Japan, ³o, Osaka, Japan, ⁴Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan, ⁵Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, ⁶Orthopaedic Surgery, Osaka City University Medical School, Osaka, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falls and fractures. The…
Abstract Number: 2593 • 2016 ACR/ARHP Annual Meeting
The Effect of Tofacitinib on Bone Mineral Density in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
Kensuke Kume¹, Kanzo Amano², Susumu Yamada¹, Toshikatsu Kanazawa³, Kazuhiko Hatta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology., hiroshima clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴Rheumatology, Hatta Clinic, Kure, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: To analyze the effects of therapy with tofacitinib (Tofa), a Janus kinase inhibitor on the bone mineral density (BMD) of the lumbar spine and…
Abstract Number: 2986 • 2016 ACR/ARHP Annual Meeting
Trends and Determinants of Osteoporosis Prevention and Management in Patients with Rheumatoid Arthritis Compared to Osteoarthritis
Gulsen Ozen^1,2, Diane L. Kamen³, Ted R Mikuls², Frederick Wolfe⁴ and Kaleb Michaud^2,4, ¹Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Despite more aggressive treatment strategies and new biologic DMARDs, the prevalence of osteoporosis (OP) leading to fracture in RA remains high. It is unknown…
Abstract Number: 2 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA)-Related Autoimmunity and Lumbar Bone Mineral Density in a Multi-Ethnic Community-Dwelling Population
Jan M. Hughes-Austin¹, Joachim H. Ix², Michael H. Criqui³, Ronit Katz⁴, Matthew Budoff⁵, Jon T. Giles⁶, Kiang Liu⁷ and Darcy S. Majka⁸, ¹Orthopaedic Surgery, University of California, San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA, ³Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁴University of Washington, Seattle, WA, ⁵Cardiology, Harbor-UCLA Medical Center, Torrance, CA, ⁶Rheumatology, Columbia University Medical Center, NY, NY, ⁷Department of Preventive Medicine, Northwestern University, Chicago, IL, ⁸Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Previous studies suggest that antibodies to citrullinated protein antigens (ACPA) contribute to decreased hand bone mineral density (BMD) in RA-free individuals. No evidence exists…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].